MDD Cohort: Meet DSM-5 criteria for Major Depressive Disorder by structured interview (MINI-KID); CDRS-R score >40; Failure to achieve remission with at least 1 adequate prior antidepressant trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing.
Anxiety Cohort: Meet DSM-5 criteria for any of the following anxiety disorders: Social Anxiety Disorders, Generalized Anxiety Disorder, Separation Anxiety Disorder and/or Panic Disorder by structured interview (MINI-KID); ADIS Clinical Severity Rating ≥4 (moderately severe) for any of the 4 included anxiety disorders; Failure to achieve remission with at least 1 adequate prior anxiolytic medication trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing; Failure to achieve remission with previous CBT or subject declines current CBT therapy
Stable psychiatric medications and doses for the month prior to enrollment. Subjects may continue to engage in any ongoing psychotherapy.
Medically and neurologically healthy on the basis of physical examination and medical history.
Parents able to provide written informed consent and adolescents must additionally provide assent.

NCT02579928_inc_T1
Observation
MDD Cohort
NCT02579928_inc_T2
Qualifier
DSM-5 criteria
NCT02579928_inc_T3
Condition
Major Depressive Disorder
NCT02579928_inc_T4
Procedure
structured interview
NCT02579928_inc_T5
Procedure
MINI-KID
NCT02579928_inc_T6
Measurement
CDRS-R score
NCT02579928_inc_T7
Value
>40
NCT02579928_inc_T8
Negation
Failure
NCT02579928_inc_T9
Condition
remission
NCT02579928_inc_T10
Multiplier
at least 1
NCT02579928_inc_T11
Qualifier
adequate
NCT02579928_inc_T12
Procedure
antidepressant trial
NCT02579928_inc_T13
Drug
SSRI
NCT02579928_inc_T14
Temporal
prior
NCT02579928_inc_T15
Drug
SNRI
NCT02579928_inc_T16
Drug
TCA
NCT02579928_inc_T17
Scope
SSRI, SNRI, or TCA
NCT02579928_inc_T18
Multiplier
at least 8 weeks
NCT02579928_inc_T19
Procedure
therapeutic dosing
NCT02579928_inc_T20
Multiplier
at least 4 weeks
NCT02579928_inc_T21
Procedure
stable dosing
NCT02579928_inc_T22
Scope
at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing
NCT02579928_inc_T23
Scope
at least 1 adequate prior antidepressant trial (e.g. SSRI, SNRI, or TCA)
NCT02579928_inc_T24
Observation
Anxiety Cohort
NCT02579928_inc_T25
Qualifier
DSM-5 criteria
NCT02579928_inc_T26
Condition
anxiety disorders
NCT02579928_inc_T27
Condition
Social Anxiety Disorders
NCT02579928_inc_T28
Condition
Generalized Anxiety Disorder
NCT02579928_inc_T29
Condition
Separation Anxiety Disorder
NCT02579928_inc_T30
Condition
Panic Disorder
NCT02579928_inc_T31
Procedure
structured interview
NCT02579928_inc_T32
Procedure
MINI-KID
NCT02579928_inc_T33
Scope
Social Anxiety Disorders, Generalized Anxiety Disorder, Separation Anxiety Disorder and/or Panic Disorder
NCT02579928_inc_T34
Measurement
ADIS Clinical Severity Rating
NCT02579928_inc_T35
Value
≥4
NCT02579928_inc_T36
Qualifier
moderately severe
NCT02579928_inc_T37
Scope
ADIS Clinical Severity Rating ≥4
NCT02579928_inc_T38
Condition
anxiety disorders
NCT02579928_inc_T39
Condition
remission
NCT02579928_inc_T40
Negation
Failure
NCT02579928_inc_T41
Multiplier
at least 1
NCT02579928_inc_T42
Qualifier
adequate
NCT02579928_inc_T43
Temporal
prior
NCT02579928_inc_T44
Procedure
anxiolytic medication trial
NCT02579928_inc_T45
Drug
anxiolytic medication
NCT02579928_inc_T46
Drug
antidepressant
NCT02579928_inc_T47
Drug
SSRI
NCT02579928_inc_T48
Drug
SNRI
NCT02579928_inc_T49
Drug
TCA
NCT02579928_inc_T50
Scope
SSRI, SNRI, or TCA
NCT02579928_inc_T51
Multiplier
at least 8 weeks
NCT02579928_inc_T52
Procedure
therapeutic dosing
NCT02579928_inc_T53
Multiplier
at least 4 weeks
NCT02579928_inc_T54
Procedure
stable dosing
NCT02579928_inc_T55
Temporal
previous
NCT02579928_inc_T56
Procedure
BT herapy
NCT02579928_inc_T57
Observation
subject declines
NCT02579928_inc_T58
Temporal
current
NCT02579928_inc_T59
Procedure
CBT therapy
NCT02579928_inc_T60
Condition
remission
NCT02579928_inc_T61
Negation
Failure
NCT02579928_inc_T62
Scope
previous CBT or subject declines current CBT therapy
NCT02579928_inc_T63
Scope
at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing
NCT02579928_inc_T64
Scope
at least 1 adequate prior anxiolytic medication trial (e.g. SSRI, SNRI, or TCA)
NCT02579928_inc_T65
Scope
DSM-5 criteria for any of the following anxiety disorders: Social Anxiety Disorders, Generalized Anxiety Disorder, Separation Anxiety Disorder and/or Panic Disorder by structured interview (MINI-KID); ADIS Clinical Severity Rating ≥4 (moderately severe) for any of the 4 included anxiety disorders; Failure to achieve remission with at least 1 adequate prior anxiolytic medication trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing; Failure to achieve remission with previous CBT or subject declines current CBT therapy
NCT02579928_inc_T66
Scope
Meet DSM-5 criteria for Major Depressive Disorder by structured interview (MINI-KID); CDRS-R score >40; Failure to achieve remission with at least 1 adequate prior antidepressant trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing
NCT02579928_inc_T67
Qualifier
Stable
NCT02579928_inc_T68
Drug
psychiatric medications
NCT02579928_inc_T69
Multiplier
able p ses f
NCT02579928_inc_T70
Temporal
for the month prior to enrollment
NCT02579928_inc_T71
Reference_point
enrollment
NCT02579928_inc_T73
Condition
neurologically healthy
NCT02579928_inc_T74
Condition
ically an lthy on
NCT02579928_inc_T75
Procedure
physical examination
NCT02579928_inc_T76
Observation
medical history
NCT02579928_inc_T77
Scope
physical examination and medical history
NCT02579928_inc_T78
Scope
Medically and neurologically healthy
NCT02579928_inc_T79
Person
Parents
NCT02579928_inc_T80
Observation
provide written informed consent
NCT02579928_inc_T81
Person
adolescents
NCT02579928_inc_T82
Observation
provide assent